Sandy Cove Advisors’s BioLineRX BLRX Stock Holding History

Sandy Cove Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90	Closed	-$6K	–	109
2022 Q1	$6K	Hold	90	–	–	0.01%	343
2021 Q4	$7K	Buy	+90	New	+$9.38K	0.01%	309

Other funds holding BLRX

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sandy Cove Advisors's BLRX Position: Q2 2022 in Review

Sandy Cove Advisors sold out of BioLineRX (BLRX) in Q2 2022, closing a stake of 90 shares — an estimated $6K sold.

Sandy Cove Advisors first reported a position in BLRX in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q4 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2022.

Sandy Cove Advisors reported no remaining BioLineRX position as of Q2 2022 after selling out during the quarter.
Sandy Cove Advisors sold 90 BioLineRX shares in Q2 2022, an estimated $6K.
Sandy Cove Advisors first reported a position in BioLineRX in Q4 2021 and held it in 2 quarters.
Sandy Cove Advisors's BioLineRX position peaked at $7K in Q4 2021.
28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2022.

Based on Sandy Cove Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.